Systemic nanoparticle paclitaxel (nab-Paclitaxel) for in-stent restenosis I (SNAPIST-I): A first-in-human safety and dose-finding study

Clinical Cardiology

Volumn 30, Issue 4, 2007, Pages 165-170

  Margolis, James ^a   McDonald, John ^b   Heuser, Richard ^c   Klinke, Peter ^b   Waksman, Ron ^d   Virmani, Renu ^e   Desai, Neil ^f   Hilton, David ^b,g  

^a Miami International Cardiology Consultants   (United States)

^b ROYAL JUBILEE HOSPITAL   (Canada)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e CVPATH INSTITUTE   (United States)

^f Abraxis BioScience Inc   (United States)

^g Victoria Heart Institute Foundation   (Canada)

Author keywords

Albumin bound paclitaxel; Drug eluting stent; Percutaneous coronary intervention; Systemic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CLOPIDOGREL; NAB PACLITAXEL; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LEUKOPENIA; MALE; NEUTROPENIA; OPTIMAL DRUG DOSE; PRURITUS; SENSORY NEUROPATHY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NANOPARTICLES; PACLITAXEL; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247388380     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20066     Document Type: Article

References (17)

1. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, et al.: TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42
2. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, et al.: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions (TAXUS II). Circulation 2003;108:788-794
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS IV trial. Circulation 2004;109:1942-1947
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease (TAXUS IV). N Engl J Med 2004;350:221-231
5. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803
6. Desai N, Trieu V, Yao R, Labao E, Soon-Shiong P: Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (ABI-007) by gp60-receptors: A pathway inhibited by taxol. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2004; (abstr 1071)
7. Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, et al.: Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity. Cancer 2001;92(10):2592-2602
8. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, et al.: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-7793
9. Blum JL, Savin MA, Edelman G, Pippen JE, Robert N, et al.: Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Proc Am Soc Clin Oncol 2004;23:12 (abstr 543)
10. O'Shaughnessy JA, Blum JL, Sandbach JF, Savin M, Fenske E, et al.: Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Presented at The 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2004
11. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, et al.; Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-6026
12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003; (http: //ctep.cancer.gov), Publish Date: December 12, 2003
13. Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llauradó C, et al.: Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003;15:581-584
14. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, et al., (OSIRIS investigators); Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis. The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial. Circulation 2004;110:790-795
15. Waksman R, Ajani AE, Pichard AD. Torguson R, Pinnow E, et al., (ORBIT investigators): Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) Study. J Am Coll Cardiol 2004;44:1386-1392
16. Chaves A, Sousa AGMR, Mattos LA, Abizaid A, Feres F, et al.: Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: A serial intravascular ultrasound study. Catheter Cardiovasc Interv 2005;66:535-540
17. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, et al.: Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-1198